BVSMEDIUM SIGNALFINANCIAL10-K

BVS demonstrated substantially improved cash generation and strengthened balance sheet positioning with reduced debt obligations and higher equity levels.

The company's operating cash flow improved meaningfully, suggesting better working capital management and operational efficiency. The substantial reduction in current liabilities combined with increased stockholders' equity indicates improved financial flexibility and reduced near-term liquidity pressures.

Comparing 2026-03-05 vs 2025-03-11View on EDGAR →
FINANCIAL ANALYSIS

BVS showed strong financial improvement across multiple metrics, with operating cash flow substantially higher year-over-year while maintaining steady cash reserves that grew modestly to $51.2M. The balance sheet strengthened considerably with stockholders' equity increasing 24% to $184.1M and total liabilities declining 16% to $455.1M, primarily driven by a significant 24% reduction in current liabilities. The company also reduced inventory levels by 11% and scaled back R&D expenses slightly, suggesting improved operational discipline alongside the enhanced cash generation.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+92.5%
$38.8M$74.7M

Operating cash flow surged 92.5% — exceptional cash generation, highest quality earnings signal.

Stockholders Equity
Balance Sheet
+24.4%
$147.9M$184.1M

Equity base grew 24.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Liabilities
Balance Sheet
-23.8%
$210.4M$160.4M

Current liabilities reduced — improved short-term financial position and working capital health.

Cash & Equivalents
Balance Sheet
+23.2%
$41.6M$51.2M

Cash grew 23.2% — improving liquidity position supports investment and shareholder returns.

Total Liabilities
Balance Sheet
-16.1%
$542.4M$455.1M

Liabilities reduced 16.1% — deleveraging improves balance sheet strength and financial flexibility.

R&D Expense
P&L
-11.2%
$13.6M$12.1M

R&D spending cut 11.2% — could signal cost discipline or concerning reduction in innovation investment.

Inventory
Balance Sheet
-11.1%
$92.5M$82.2M

Inventory reduced 11.1% — lean inventory management or demand outpacing supply.

LANGUAGE CHANGES
NEW — 2026-03-05
PRIOR — 2025-03-11
ADDED
As of February 27, 2026, there were 67,368,052 shares of Class A common stock outstanding and 15,786,737 shares of Class B common stock outstanding.
Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements including, without limitation, statements concerning: our future financial results and liquidity; our business strategy, position and operations; and expected sales trends, opportunities, market position and growth.
Table of C o ntents SUMMARY OF PRINCIPAL RISK FACTORS We are subject to several risks, including risks that may prevent us from achieving our business objectives or that may adversely affect our business, results of operations, financial condition, and cash flows.
Risk Factors , including the following principal risks: our 2025 Credit Agreement contains financial and operating restrictions that could limit our access to credit.
Our portfolio of products is comprised of five patient-focused areas, grouped into three businesses based on clinical use: (i) Pain Treatments PRP ( Pain Treatments ), (ii) Surgical Solutions and (iii) Restorative Therapies.
+7 more — sign up free →
REMOVED
As of February 27, 2025, there were 66,156,868 shares of Class A common stock outstanding and 15,786,737 shares of Class B common stock outstanding.
Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements including, without limitation, statements concerning our future financial results and liquidity; the impact of our recently divested Advanced Rehabilitation Business on our financial condition and operations; our business strategy, position and operations; and expected sales trends, opportunities, market position and growth.
Risk Factors , including the following principal risks: our Amended 2019 Credit Agreement contains financial and operating restrictions that may limit our access to credit.
We do not control the intellectual property rights covering these technologies and any loss of our rights to these technologies or the rights licensed to us could prevent us from selling our products; and our principal asset is our interest in BV LLC, and, accordingly, we depend on distributions from BV LLC to pay our taxes and expenses, including payments under the Tax Receivable Agreement.
BV LLC s ability to make such distributions may be subject to various limitations and restrictions.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →